Advice
Following a full submission
Daptomycin (Cubicin) is accepted for restricted use within NHS Scotland for the treatment of complicated skin and soft tissue infections in adults.
Daptomycin should be restricted to use in patients with known or suspected methicillinresistant Staphylococcus aureus (MRSA) infection and on the advice of local microbiologists or specialists in infectious disease.
Daptomycin has a higher acquisition cost than some alternative treatments; it does not, however, require therapeutic drug monitoring.
Download detailed advice44KB (PDF)
Medicine details
- Medicine name:
- Daptomycin (Cubicin)
- SMC ID:
- 248/06
- Indication:
- Complicated skin and soft tissue infections in adults
- Pharmaceutical company
- Chiron Biopharmaceuticals
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 April 2006